Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State

(2015) David S. Small et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib

(2014) Brett Lauring et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

(2014) Jeffrey G. Suico et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

(2013) Antonio M. Gotto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk

(2013) Nathan B. Mantlo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors

(2012) Shenping Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

(2011) Rajesh Krishna et al.   AAPS Journal

Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia

(2011) Hayes M. Dansky et al.   AMERICAN HEART JOURNAL

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

(2011) Malcolm Rowland et al.   Annual Review of Pharmacology and Toxicology

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

(2011) D E Gutstein et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

(2009) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

(2009) Rajesh Krishna et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods

(2009) Patrick Poulin et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL